Biologics (Etanercept, Infliximab, Adalimumab, Ustekinumab, Secukinumab, Ixekizumab, Guselkumab, Tildrakizumab)
Noted DermatologyLater-line line
Chronic plaque psoriasis in patients with baseline PASI ≥ 12 to ≤ 15 who have failed to achieve adequate response to at least two conventional therapies (phototherapy, methotrexate, ciclosporin, or acitretin).
1
Submissions
1 resub
2020–20
On the record
$105k–200k
ICER range
1 sourced ICER · 2020
ICER stated
Cost basis
Access path
- Jul 2020Noted
vs placebo
- PBS listing
RecommendedDeferredNot recommended
From the public summary
PBAC outcome
4.1 The PBAC noted the Sponsor pre-PBAC responses and one stakeholder submission.PSD · Jul 2020
4.2 The PBAC recalled that in its April 2018 consideration of the PMR report for biologics in CPP, “the PBAC requested a CER to consider the additional PBS population’s treated with biologics that meet the eligibility criteria of a baseline PASI of ≥ 12 to ≤ 15 and a DLQI > 10.PSD · Jul 2020
Cost-effectiveness
Base case ICER for PASI ≥12 to ≤15 population. Existing ICER for PASI >15 was $15,000–$45,000/QALY.
The Base case ICER, in patients with a baseline PASI of ≥ 12 and ≤ 15, was $105,000/QALY – $200,000/QALY. PSD · 2020
ICER / price too highSurrogate endpoint
Decision context
PopulationPatients with chronic plaque psoriasis with baseline PASI ≥ 12 to ≤ 15 who have failed at least two conventional therapies (phototherapy, methotrexate, ciclosporin, or acitretin).
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Jul 2020 | Noted | placebo | $105k–200k | RCT · PASI 75 |